GlassScriptPhysician profile
Zev M Cohen
NPI 1881732758
$5,354.59
in general payments reported to CMS, 2019-2025
29 companies · $668 in 2025
The $668 reported for 2025 was more than what 78% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $617 · 2020: $577 · 2021: $822 · 2022: $765 · 2023: $737 · 2024: $1,169 · 2025: $668.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,559 · Education: $14.85.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,559.04 |
| Education | $14.85 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $604.01 | 2021-2025 | Fasenra, Breztri |
| Pfizer INC. | $531.35 | 2020-2025 | |
| Orexo US, INC. | $380.13 | 2020-2025 | Zubsolv |
| Abbvie INC. | $373.97 | 2021-2025 | Vraylar |
| Allergan, INC. | $366.43 | 2019-2020 | |
| Kowa Pharmaceuticals America, INC. | $281.52 | 2019-2022 | |
| Indivior INC. | $263.78 | 2019-2024 | Sublocade |
| Amgen INC. | $247.94 | 2019-2025 | Otezla, Repatha, Otezla |
| Idorsia Pharmaceuticals US INC | $234.10 | 2022-2024 | Quviviq |
| Amarin Pharma, INC. | $217.45 | 2019-2022 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $205.57 | 2025 | Caplyta |
| Novo Nordisk INC | $188.48 | 2021-2024 | Ozempic, Rybelsus |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $174.17 | 2023-2025 | Xifaxan |
| Braeburn INC. | $157.44 | 2024-2025 | Brixadi |
| Exact Sciences Corporation | $157.40 | 2023-2025 | Cologuard Collection Kit |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcresta Therapeutics, INC. | $130.75 | 2022 | |
| Axsome Therapeutics, INC. | $122.29 | 2024 | Auvelity |
| Novartis Pharmaceuticals Corporation | $99.91 | 2023-2025 | |
| Alkermes, INC. | $99.41 | 2025 | Vivitrol |
| Antares Pharma, INC. | $94.76 | 2019-2021 | |
| Shield Therapeutics INC | $84.65 | 2024 | |
| Gilead Sciences, INC. | $84.54 | 2019-2022 | |
| Collegium Pharmaceutical, INC. | $72.25 | 2023-2025 | Belbuca |
| Arbor Pharmaceuticals, INC. | $49.74 | 2019-2021 | |
| Grt US Holding, INC. | $47.22 | 2021 | |
| Ultragenyx Pharmaceutical INC. | $23.44 | 2021 | |
| Janssen Pharmaceuticals, INC | $22.48 | 2022 | |
| Abbott Laboratories | $19.73 | 2021 | |
| Eisai INC. | $19.68 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Zev Cohen listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.